Anti-RBD antibody and neutralizing antibody at baseline and at
one year
The baseline anti-RBD antibody (U/mL) and neutralizing antibody (%)
titer in cirrhotic and HCW was 0.675 (0.4-10478) & 54.7 (0.04-1403.0)
and 11.2 (-17.39-97.35) and 15.02 (-10.04-97.3) respectively. Three
patients in cirrhotic group had higher levels of anti-RBD antibody and
NAbs levels even before vaccination which could be due to asymptomatic
natural SARSCoV-2 infection. All participants in cirrhotic and HCW group
showed development of antibodies and the median titers after one year
were 2132 (11.09-42594) & 8444 (101.6-23044) and 35.57 (-22.29-97.4)
and 94.3 (-0.8-97.6) respectively. There was no difference between
anti-RBD and neutralizing antibody titer at one year between cirrhotic
and HCW group (P=0.312, P=0.277). The unvaccinated group had
<0.4U/mL and <20% anti-RBD antibody (U/mL) and
neutralizing antibody levels. (Figure-2)